OCT Launches Cost-Effective Bioequivalence Studies Amidst Rising Market Demand

OCT, a leading Eastern European CRO, announces a strategic expansion with a new focus on accessible bioequivalence studies. By integrating leading research centers and labs, OCT provides optimized bioequivalence solutions, addressing the growing need for cost-effective development of generics and biosimilars, particularly in the evolving Russian market.

Pharmaceutical companies are prioritizing R&D cost optimization without compromising quality or regulatory standards. Bioequivalence studies are essential for delivering affordable, high-quality medicines. Leveraging over 20 years of experience and more than 350 completed projects since 2005, OCT offers expertise, reliability, and affordability.

What makes OCT a valuable partner? The company offers:

• Direct lab contracts for transparent pricing and budget control.
• Over 380 validated analytical methods to guarantee accurate, reliable results for regulatory approval.
• Synchronized QMS policies.
• Package discounts.
• Commercial proposal calculation within 3 days.
• Fast procurement of reference standards (1-2 months).
• Biowaiver execution — reduces study timelines and costs.
• Comparative dissolution kinetic testing (CDKT) — optimizes drug formulation development and registration.
• GCP & GLP compliance, adhering to GOST 22044.
• ‘Single Window’ approach — dedicated personal manager for streamlined communication and issue resolution.

“We understand that competitiveness in today’s pharmaceutical market directly depends on cost efficiency and speed to market,” stated Dmitry Sharov, CEO of OCT. “That’s why we’ve developed a specialized offering, integrating top units and labs to save our clients time and resources, delivering fast, reliable bioequivalence results without compromising quality.”

OCT’s full-service package covers study documentation, project management, subject recruitment via accredited centers and labs, data management, statistical analysis, and final report preparation. OCT ensures a tailored approach, meeting specific client needs. Key partners include renowned research centers such as Yaroslavl Regional Clinical Narcological Hospital, North-Western Scientific Center of Hygiene and Public Health, Rostov Central District Hospital, Smorodintsev Research Institute of Influenza, and laboratories like ‘Sivilab’ and ‘Kvinta-Analitika Yaroslavl’.

OCT CRO is committed to advancing the Russian pharmaceutical market by providing accessible, high-quality bioequivalence solutions, thereby enhancing access to medicines for the public.